Publications

2009

Original Articles

Asmus F, Langseth A, Doherty E, Nestor T, Munz M, Gasser T, Lynch T, King MD (2009) "Jerky" dystonia in children: spectrum of phenotypes and genetic testing. Mov Disord. 2009 Apr 15;24(5):702-9.

Asmus F, von Coelln R, Boertlein A, Gasser T, Mueller J. (2009) Reverse sensory geste in cervical dystonia. Mov Disord. 2009 Jan 30;24(2):297-300.

Bauer M, Kinkl N, Meixner A, Kremmer E, Riemenschneider M, Förstl H, Gasser T, Ueffing M. (2009) Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 2009 Jan;16(1):142-7.

Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group. (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 Jan;132(Pt 1):156-71.

Breit S, Wächter T, Schöls S, Gasser T, Nägele T, Freudenstein D, Krüger R. (2009) Effective thalamic deep brain stimulation for neuropathic tremor in a patient with severe demyelinating neuropathy. J Neurol Neurosurg Psychiatry. J Neurol Neurosurg Psychiatry 80: 235-36.

Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. (2009) ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord. 2009 Aug 24.

Evangelou E , Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krüger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quatrone A, Sharma M, Silburn PA, Tan EK, Van Broeckhoven C, Wirdefeldt K, Ioannidis JPA, for the Genetic Epidemiology of Parkinson’s disease (GEOPD) consortium. (2009) Non-replication of association for 6 polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease: large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet.

Fernández-Santiago R, Sharma M, Berg D, Illig T, Anneser J, Meyer T, Ludolph A, Gasser T. No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort.
Neurobiol Aging. 2009 May 21.

Fernández-Santiago R, Hoenig S, Lichtner P, Sperfeld AD, Sharma M, Berg D, Weichenrieder O, Illig T, Eger K, Meyer T, Anneser J, Münch C, Zierz S, Gasser T, Ludolph A. (2009) Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol. 2009 Aug;256(8):1337-42.

Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wüllner U, Illig T, Sharma M, Gasser T. (2009) The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging. 2009 May;30(5):731-8.

Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. (2009) Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord. 2009 Aug;15(7):539-41.

Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H. (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009 Jun;70(6):922-31.

Kahle PJ, Waak J, Gasser T. (2009) DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med. 2009 Aug 14.

Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem. 2009 Aug 27.

Koch A, Lehmann-Horn K, Dächsel JC, Gasser T, Kahle PJ, Lücking CB. (2009) Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells. Parkinsonism Relat Disord. 2009 Mar;15(3):220-5.

Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C. (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis. 2009 Mar;16(3):649-56.

Madžar D, Schulte C, Gasser T. (2009) Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany. Eur J Neurol. 2009 Jun 15.

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D. (2009) No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009 Aug;35(2):296-301.

Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D. (2009) A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm. 2009 May;116(5):599-605.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009 Apr;34(1):107-12.

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268-78.

Robottom BJ, Weiner WJ, Asmus F, Huber H, Gasser T, Schöls S. (2009) Kick and rush: paradoxical kinesia in Parkinson disease. Neurology. 2009 Jul 28;73(4):328; author reply 328-9.

Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Miesel F, Sharma M, Bornemann A, Berg D, Gasser T, Patenge N. (2009) Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet. 2009 Oct 15;18(20):3832-50.

Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009 May;65(5):610-4.

Schulte C, Synofzik M, Gasser T, Schöls S. (2009) Ataxia with ophthalmoplegia or sensory neuropathy is frequently caused by POLG mutations. Neurology. 2009 Sep 15;73(11):898-900.

Sharma M, Lichtner P,  Krüger R, Berg D, Schulte C,  Illig T, Riess O, Gasser T. (2009) Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging 30: 1706-9.

Sidransky E, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen C-M, Clark LN, Condroyer C, de Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer M, Fung H-C, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen G-J, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nalls MA, Nicoletti G, Oliveira C, Ottman R , Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton S, Spitz M, TanE-K, Tayebi N, Toda T, Troiano A, Tsuji S, Wittstock M, Wolfsberg TG, Wu Y-R, Zabetian CP, Zhao Y, Ziegler SG (2009) International multi-center analysis of glucocerebrosidase mutations in Parkinson disease. New Engl J Med.

Simon-Sanchez J, Schulte C, Bras CM, Sharma M, Gibbs R, Berg D, Paison-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Fedoroff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Foote KD,  Fernandez HH, Schreiber S, Arepalli S, Zonozi R, Gwinn K, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T.  (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet.

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, da Costa CA, Riess O. (2009)  Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics. 2009 Sep 3.

Wächter T, Weiss D, Breit S, Gasser T, Krüger R, Gharabaghi A. (2009) Severe muscular fasciculations as an uncommon side-effect due to microdefect of an extension wire in deep brain stimulation. Mov Disord. 2009 Aug 24.

Zimprich A, Schulte C, Reinthaler E, Haubenberger D, Balzar J, Lichtner P, El Tawil S, Edris S, Foki T, Pirker W, Katzenschlager R, Daniel G, Brücke T, Auff E, Gasser T. (2009) PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism Relat Disord. 2009 Aug;15(7):532-4.

Reviews

Harbo HF, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Schöls S, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen C, Zeviani M, Burgunder JM, Gasser T; EFNS. (2009) EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol. 2009 Jul;16(7):777-85.

Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK; Reisensburg Working Group for Tauopathies With Parkinsonism. (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009 Mar;16(3):297-309.

Gasser T. (2009) Genomic and proteomic biomarkers for Parkinson disease. Neurology. 2009 Feb 17;72(7 Suppl):S27-31.

Gasser T. (2009) Mendelian forms of Parkinson's disease. Biochim Biophys Acta. 2009 Jul;1792(7):587-96.

Gasser T. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009 Jul 27;11
Schulz JB, Boesch S, Bürk K, Dürr A, Giunti P, Mariotti C, Pousset F, Schöls S, Vankan P, Pandolfo M. (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009 Apr;5(4):222-34.


2008

Original Articles

Asmus F, Huber H, Gasser T, Schöls S (2008) Kick and rush: paradoxical kinesia in Parkinson disease. Neurology 71(9):695

Bach J, Sommer N, Möller JC, Oertel WH, Dodel R, Gasser T (2008) Parkinson’s syndrome in a young patient with Klinefelter’s syndrome--a case report. Movement Disorders 23(5):771-2

Bauer M, Szulc J, Meyer M, Jensen CH, Terki TA, Meixner A, Kinkl N, Gasser T, Aebischer P, Ueffing M (2008) Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons. Journal of Neurochemistry 104(4):1101-15

Breit S, Martin A, Lessmann L, Cerkez D, Gasser T, Schulz JB (2008) Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model. Journal of Neuroscience Research 86(6):1388-96

Breit S, Spieker S, Schulz JB, Gasser T (2008) Long-term EMG recordings differentiate between parkinsonian and essential tremor. Journal of Neurology 255(1):103-11

Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. The FASEB Journal 22(5):1327-34

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla H, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurology 7(5):417-24

Gasser T (2008) Hunting for genes and mutations: it’s worth remembering the basics. Neurology 70(16 Pt 2):1373-4

Godau J, Wevers A, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D (2008) Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Medicine 9(7):782-9

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan E, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70(16 Pt 2):1456-60

Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AHV, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurology 7(7):583-90

Hoepken H, Gispert S, Azizov M, Klinkenberg M, Ricciardi F, Kurz A, Morales-Gordo B, Bonin M, Riess O, Gasser T, Kögel D, Steinmetz H, Auburger G (2008) Parkinson patient fibroblasts show increased alpha-synuclein expression. Experimental Neurology 212(2):307-13
Kamm C, Fischer H, Garavaglia B, Kullmann S, Sharma M, Schrader C, Grundmann K, Klein C, Borggräfe I, Lobsien E, Kupsch A, Nardocci N, Gasser T (2008) Susceptibility to DYT1 dystonia in European patients is modified by the D216H polymorphism. Neurology 70(23):2261-2

Kamm C, Fogel W, Wächter T, Schweitzer K, Berg D, Kruger R, Freudenstein D, Gasser T (2008) Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology 70(16 Pt 2):1501-3

Kamm C, Nägele T, Mittelbronn M, Schöning M, Melms A, Gasser T, Schöls S (2008) Primary central nervous system vasculitis in a child mimicking parasitosis. Journal of Neurology 255(1):130-2

Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Østergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK (2008) Red flags for multiple system atrophy. Movement Disorders 23(8):1093-9

Liepelt I, Maetzler W, Blaicher H, Gasser T, Berg D (2008) Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors. Der Nervenarzt 79(1):36-9, 42-6

Lücking CB, Lichtner P, Dichgans M, Illig T, Gieger C, Berg D, Gasser T (2008) Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson’s disease. Journal of Neurology 255(3):441-2

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla H, Bares R, Berg D (2008) [11C]PIB binding in Parkinson’s disease dementia. NeuroImage 39(3):1027-33

Prestel J, Gempel K, Hauser T, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T (2008) Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. Journal of Neurology 255(5):643-8

Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin M, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Annals of Neurology 63(6):743-50

Trenkwalder C, Boesch S, Ceballos-Baumann A, Dressler D, Eggert K, Gasser T, Honig H, Müller T, Reichmann H, Sieb JP, Storch A, Odin P, Poewe W (2008) Intermittent apomorphine injections as rescue therapy for advanced Parkinson’s disease. Consensus statement. Der Nervenarzt 79(4):475-9

von Coelln R, Raible A, Gasser T, Asmus F (2008) Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Movement Disorders 23(6):889-92

Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, Maljevic S, Margari L, Kamm C, Schneider SA, Huber SM, Pekrun A, Roebling R, Seebohm G, Koka S, Lang C, Kraft E, Blazevic D, Salvo-Vargas A, Fauler M, Mottaghy FM, Münchau A, Edwards MJ, Presicci A, Margari F, Gasser T, Lang F, Bhatia KP, Lehmann-Horn F, Lerche H (2008) GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. The Journal of Clinical Investigation 118(6):2157-68
Reviews

Biskup S, Gerlach M, Kupsch A, Reichmann H, Riederer P, Vieregge P, Wüllner U, Gasser T (2008) Genes associated with Parkinson syndrome. Journal of Neurology 255 Suppl 5:8-17

Gaenslen A, Gasser T, Berg D (2008) Nutrition and the risk for Parkinson’s disease: review of the literature. Journal of Neural Transmission (Vienna, Austria: 1996) 115(5):703-13


Books, book chapters, and proceedings

Gasser T (2008) Biomarker für neurodegenerative Erkrankungen. In: Schmitz G, Endres S, Götte D (eds): Biomarker: Bedeutung für medizinischen Fortschritt und Nutzenbewertung. Schattauer Verlag, Stuttgart, New York, 156-168


2007

Original Articles

Asmus F, Devlin A, Munz M, Zimprich A, Gasser T, Chinnery PF (2007) Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. Movement Disord 22(14):2104-9

Asmus F, Hjermind LE, Dupont E, Wagenstaller J, Haberlandt E, Munz M, Strom TM, Gasser T (2007) Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 130(10):2736-45

Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der Zee J, Sleegers K, Peeters K, Martin JJ, Del-Favero J, Gasser T, Dickson DW, Wszolek ZK, De Deyn PP, Theuns J, Van Broeckhoven C (2007) A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain 130(9):2277-91

Breit S, Bouali-Benazzouz R, Popa RC, Gasser T, Benabid AL, Benazzouz A (2007) Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp Neurol 205(1):36-47

Brötz D, Eichner M, Gasser T, Weller M, Steinbach JP (2007) Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Movement Disord 22(6):853-6

Eggert K, Wullner U, Antony G, Gasser T, Janetzky B, Klein C, Schöls S, Oertel W (2007) Data protection in biomaterial banks for Parkinson’s disease research: the model of GEPARD (Gene Bank Parkinson’s Disease Germany). Movement Disord 22(5):611-8

Exner N, Treske B, Paquet D, Holmström K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser T, Krüger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Kahle PJ, Schmid B, Haass C (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27(45):12413-8

Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68(12):916-22

Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D, Katzenschlager R, Djamshidian A, Brucke T, Steffelbauer M, Bancher C, Grossmann J, Ransmayr G, Strom TM, Meitinger T, Gasser T, Auff E, Zimprich A (2007) A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson’s disease. Movement Disord 22(11):1640-3

Kamm C, Mayer P, Sharma M, Niemann G, Gasser T (2007) New family with paroxysmal exercise-induced dystonia and epilepsy. Movement Disord 22(6):873-7

Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropath Exp Neur 66(5):329-36

Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, Jenner P, Melamed E, Myers RH, Parker D Jr, Price DL (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropath Exp Neur 66(4):251-7

Mätzler W, Berg D, Schalamberidze N, Melms A, Schott K, Müller JC, Liaw L, Gasser T, Nitsch C (2007) Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 25(3):473-82

Mätzler W, Nagele T, Gasser T, Krüger R (2007) Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology 68(6):414

Ohta E, Hasegawa K, Gasser T, Obata F (2007) Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson’s disease families. Neurosci Lett 417(1):21-3

Rosenberger A, Sharma M, Muller-Myhsok B, Gasser T, Bickeboller H (2007) Meta analysis of whole-genome linkage scans with data uncertainty: an application to Parkinson’s disease. BMC Genet 8(44):1-9

Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188(1):117-27

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Brüssel T, Wendt A, Abel F, Müller A, Gasser T, Berg D (2007) Cross-sectional study discloses a positive family history for Parkinson’s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm 114(9):1167-71

Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D (2007) Transcranial ultrasound in different monogenetic subtypes of Parkinson’s disease. J Neurol 254(5):613-16

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ (2007) Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson‘s disease. Neurogenetics 8(2):95-102

Valkovic P, Krastev G, Mako M, Leitner P, Gasser T (2007) A unique case of coincidence of early onset Parkinson‘s disease and multiple sclerosis. Movement Disord 22(15)2278-81

Reviews

Gasser T (2007) Update on the genetics of Parkinson‘s disease. Movement Disord 22(S17):S343-50

Liepelt I, Mätzler W, Blaicher HP, Gasser T, Berg D (2007) Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn 23(6):351-67

Liepelt I, Mätzler W, Blaicher HP, Gasser T, Berg D (2007) Behandlung der Demenz bei Parkinson-Syndromen. Nervenarzt 79(1):36-46

Books, book chapters, and proceedings

Gasser T (2007) Molekulargenetische Diagnostik und Gentherapie. In: Brandt T, Dichgans J, Diener HC (eds) Therapie und Verlauf neurologischer Erkrankungen, 5th edition. Kohlhammer, Stuttgart, 1519-38

Gasser T (2007) Genetics of Parkinson’s disease. In: Jankowic J, Tolosa E (eds) Parkinson’s disease and movement disorders, 5th edition. Liptincott, Williams and Wilkins, Philadelphia, 93-101

Gasser T, Danek A (2007) Chorea. In: Brandt T, Dichgans J, Diener HC (eds) Therapie und Verlauf neurologischer Erkrankungen, 5. Auflage. Kohlhammer, Stuttgart, 1089-97

Gasser T (2007) Molekulargenetische Diagnostik und Gentherapie. In: Brandt T, Dichgans J, Diener HC (eds) Therapie und Verlauf neurologischer Erkrankungen, 5th edition. Kohlhammer, Stuttgart, 1519-38

Schulz JB, Gasser T (2007) Parkinson-Syndrome. In: Brandt T, Dichgans J, Diener HC (eds) Therapie und Verlauf neurologischer Erkrankungen, 5. Auflage. Kohlhammer, Stuttgart, 961-1007

2006

Original Articles

Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Müller-Myhsok B, Gasser T, Tatsch K, Klopstock T (2006) Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology 67:1262-4

Breit S, Lessmann L, Unterbrink D, Popa RC, Gasser T, Schulz JB (2006) Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. Eur J Neurosci 24(8):2275-82

Depboylu C, Lohmuller F, Du Y, Riemenschneider M, Kurz A, Gasser T, Muller U, Dodel RC (2006) Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoproteinreceptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci Lett 400(3):187-90

Deutschlander A, Asmus F, Marelli E, Klopstock T, Gasser T, Botzel K (2006) Excellent response to  pomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication. Movement Disord 21(9):1523-5

Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14(3):322-31

Elstner M, Bettecken T, Wasner M, Anneser F, Dichgans M, Meitinger T, Gasser T, Klopstock T( 2006) Familial carpal tunnel syndrome: further evidence for a geneticcontribution. Clin Genet 69(2):179-82

Fernandez-Santiago R, Sharma M, Mueller C, Gohlke H, Illig T, Anneser J, Münch C, Ludolph A, Kamm C, Gasser T (2006) Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. Neurology 66:1929-31

Gasser T (2006) Molecular genetic findings in LRRK2 American, Canadian and German families. J Neural Transm-Supp 70:231-4

Kamm C, Asmus F, Mueller J, Mayer P, Sharma M, Muller UJ, Beckert S, Ehling R, Illig T, Wichmann HE, Poewe W, Mueller JC, Gasser T (2006) Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology 67(10):1857-9

Leyhe T, Schule R, Schwarzler F, Gasser T, Haarmeier T (2006) Second primary tumor in anti-Ma1/2-positive paraneoplastic limbicencephalitis. J Neuro-Oncol 78(1):49-51

Liebetanz KM, Winkelmann J, Trenkwalder C, Putz B, Dichgans M, Gasser T, Muller-Myhsok B (2006) RLS3: fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity. Neurology 67(2):320-1

Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW (2006) The a-synuclein gene in multiple system atrophy. J Neurol Neurosur PS 77:464-7

Prestel J, Schweitzer K, Hofer A, Gasser T, Berg D (2006) Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Movement Disord 21:1763-5

Schneider SA, Mohire MD, Trender-Gerhard I, Asmus F, Sweeney M, Davis M, Gasser T, Wood NW, Bhatia KP (2006) Familial dopa-responsive cervical dystonia. Neurology 66:599-601

Schulte C, Sharma M, Mueller JC, Lichtner P, Prestel J, Berg D, Gasser T (2006) Comprehensive association analysis of the NOS2A gene with Parkinson disease. Neurology 67(11)2080-2

Sharma M, Mueller JC, Zimprich A, Lichtner P, Hofer A, Leitner P, Maass S, Berg D, Dürr A, Bonifati V, De Michele G, Oostra B, Brice A, Wood NW, Müller-Myhsok B, Gasser T (2006) The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J Med Genet 43:557-62

Reviews

Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Sole J (2006) A systematic review on the diagnosis and treatment of primary (idiopathic)dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 13(5):433-44

Günther A, Berg D, Joachimski F, Ragoschke-Schumm A, Redecker C. Neurological picture. Acute Wernicke's encephalopathy with hyperechogenic corpora mammillaria in brain sonography. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):114-5.

Reimann M, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schoels L, Reichmann H, Berg D, Ziemssen T. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm. 2010 Jan;117(1):69-76.

Lücking CB, Lichtner P, Kramer ER, Gieger C, Illig T, Dichgans M, Berg D, Gasser T. Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany. Neurobiol Aging. 2010 Jan;31(1):167-8.

Synofzik M, Asmus F, Reimold M, Schöls L, Berg D. Sustained dopaminergic response of Parkinsonism and depression in POLG-associated Parkinsonism. Mov Disord. 2009 Dec 7. [Epub ahead of print]

Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord. 2009, 24 Suppl 2:S677-83.

Mänz C, Godau J, Berg D, Bender B, Ernemann U, Klose U. The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri. Neuroradiology. 2009 Oct 27. [Epub ahead of print]

Walter U, Skoloudík D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci. 2009 Sep 5. [Epub ahead of print]

Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, Dillmann U, Gaenslen A, Di Santo A, Maetzler W, Berg D. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging. 2009 Nov 6. [Epub ahead of print]

Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009 Dec;8(12):1158-71.

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.

Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C,et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009 Dec;41(12):1308-12.

Schmidt C, Berg D; Herting, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Ziemssen T. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009 Oct 30;24(14):2136-42.

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, da Costa CA, Riess O. Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics. 2009 Sep 3. [Epub ahead of print]

Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord. 2009 Oct 30;24(14):2104-11.

Funke C, Soehn AS, Tomiuk J, Riess O, Berg D. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm. 2009 Apr;116(4):443-50.

Funke C, Tomiuk J, Riess O, Berg D, Soehn AS. Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm. 2009 Jul;116(7):853-9.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm. 2009 Jul;116(7):875-80.

Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage. 2009 Oct 1;47(4):1237-43.

Guthoff M, Tschritter O, Berg D, Liepelt I, Schulte C, Machicao F, Haering HU, Fritsche A. Effect of genetic variation in Kv1.3 on olfactory function. Diabetes Metab Res Rev. 2009 Sep;25(6):523-7.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[(18)F]FDG-PET. Mov Disord. 2009 Jul 30;24(10):1504-11.

Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord. 2009 Aug;15(7):539-41.

Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D. A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm. 2009 May;116(5):599-605.

Sharma M, Lichtner P, Kruger R, Berg D, Schulte C, Illig T, Riess O, Gasser T. Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging. 2009 Oct;30(10):1706-9.

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009 Aug;35(2):296-301.

Godau J, Manz A, Wevers AK, Gaenslen A, Berg D. Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord. 2009 Jan 15;24(1):133-7.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009 Apr;34(1):107-12.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Reichmann H, Berg D, Ziemssen T.Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord. 2008 Oct 30;23(14):2083-9.

Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Berg D, Reichmann H, Ziemssen T. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm. 2008 Nov;115(11):1527-36.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord. 2008 Sep 15;23(12):1766-72.

Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008 Nov;7(11):1044-55.

Kamm C, Fogel W, Wächter T, Schweitzer K, Berg D, Kruger R, Freudenstein D, Gasser T. Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology. 2008 Apr 15;70(16 Pt 2):1501-3.

Schroeder C, Walter M, Berg D, Leitner P, Bauer P, Kohl Z, Winkler J, Riess O, Bonin M. High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. J Mol Diagn. 2008 May;10(3):217-24.

Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis. 2008;5:133-6.

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla H.-J., Reimold M, Marek K, Berg D. Prospective evaluation of the specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2008 May;7(5):417-24.

Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome, Mov Disord. 2008 Jun 15;23(8):1184-7.

Liepelt I, Wendt A, Schweitzer K.J., Wolf B, Godau J, Gaenslen A, Bruessel T, Berg D. Substantia nigra hyperechogenicity assessed by Transcranial Sonography is related to neuropsychological impairment in the elderly population. J Neural Transm. 2008 Jul;115(7):993-9.

Unger MM, Möller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Hoeffken H, Mayer G, Oertel WH. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord. 2008 Mar 15;23(4):596-9.

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1456-60.

Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol. 2008 May;255(5):643-8.

Gaenslen A, Gasser T, Berg D. Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm. 2008 115(5):703-13.

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-33.

Godau J, Wevers AK, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med. 2008 Oct;9(7):782-9.

Schweitzer KJ, Berg D. Transcranial ultrasound as a new instrument in the early and differential diagnosis of Parkinson's disease. CNS Drugs. 2007;21:17-24.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment for dementia in parkinsonian syndromes: Efficacy of cholinesterase inhibitors. Nervenarzt. 2008; 79:36-46.

Berg D. Ultrasound in the (premotor) diagnosis of Parkinson's disease. Parkinsonism Relat Dis. 2007;13:429-433.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Antoni S, Ferger D, Reichmann H, Wilhelm H, Berg D, Ziemssen T.Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord. 2007;22:2123-6.

Berg D. Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson's Disease: Implications for Idiopathic and Monogenetic Forms. Neurochem Res. 2007;32:1646-54.

Ruprecht-Dörfler P, Klotz P, Becker G, Berg D. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord. 2007;13:362-4.

Althaus A, Kanis T, Spottke A, Eggert K, Liepelt I, Berg D, Schneider F & Dodel R. Benchmarking in der Patientenversorgung, Depression bei der Parkinson-Krankheit - Ergebnisse der Pilotstudie. Nervenheilkunde 2007;26:277-80.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. Dement Geriatr Cogn Disord. 2007;23:351-367.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Muller A, Gasser T, Berg D. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm. 2007 Sep;114(9):1167-71.

Schweitzer KJ, Brussel T, Leitner P, Kruger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.J Neurol. 2007;254:613-6.

Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007;25:473-82.

Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22:187-192.

Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol. 2007;33:15-25.

Schols L, Nagele T, Schule R, Berg D. Cerebrotendinous xanthomatosis. Neurology. 2006;67:E20.

Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm. 2006; Suppl 71:123-32.

Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord. 2006 Sep;21(9):1299-310.

Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord. 2006; 21:1763-65.

Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U, Behnke S, Riess O, Berg D. Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett. 2006 Oct 16;407(1):16-9.

Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006;17:5-17.

Berg D, Behnke S, Walter U. Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations. Ultraschall Med. 2006;27:12-19.

Berg D, Hochstrasser H, Schweitzer K, Riess O. Disturbance of iron metabolism in Parkinson's disease - Ultrasonography as a biomarker. Neurotox Res. 2006; 9:1-13.

Schweitzer, K, Hilker, R, Walter, U, Burghaus, L, Berg, D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord. 2006;21:94-8.

Original articles

Asmus F, Schoenian S, Lichtner P, Munz M, Mayer P, Muller-Myhsok B, Zimprich A, Remschmidt H, Hebebrand J, bandmann O, Gasser T. Epsilon-Sarcoglycan (SGCE) is not involved in sporadic Gilles de la Tourette syndrome. Neurogenetics 2005; akzeptiert.

Deutschlander A, Asmus F, Gasser T, Steude U, Botzel K. Sporadic rapid-onset dystonia-parkinsonism syndrome: Failure of bilateral pallidal stimulation. Mov Disord 2004.

Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. J Biol Chem. 2004 May 7;279(19):19882-92

Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Mov Disord. 2004 Jul;19(7):845-7 

Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, Ramesh V. TorsinB--perinuclear location and association with torsinA. J Neurochem. 2004 Jun;89(5):1186-94

Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J, Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. J Neurosci Res. 2003 Apr 15;72(2):158-68

Castelon Konkiewitz E, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T, Conrad B, and Ceballos-Baumann AO. Service-based survey of dystonia in munich. Neuroepidemiology 2002, 21(4): 202-6

Bandmann O, Asmus F, Sibbing D, Grundmann M, Schwab SG, Muller J, Wildenauer DB, Poewe W, Gasser T, Oertel WH. Copper genes are not implicated in the pathogenesis of focal dystonia. Neurology 2002; 59: 782-783

Muller J, Kiechl S, Wenning GK, Seppi K, Willeit J, Gasperi A, Wissel J, Gasser T, Poewe W. The prevalence of primary dystonia in the general community. Neurology 2002; 59: 941-943.

Asmus F, Zimprich A, Tezenas Du MS, Kabus C, Deuschl G, Kupsch A, Ziemann U, Castro M, Kuhn AA, Strom TM, Vidailhet M, Bhatia KP, Durr A, Wood NW, Brice A, Gasser T. Myoclonus-dystonia syndrome: epsilon -sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489-492.

Kruse N, Berg D, Francis MJ, Naumann M, Rausch W-D, Reiners K, Rieckmann P, Weishaupt A, Becker G. Reduction of Menkes mRNA and Copper in Leucocytes of Patients with Primary Adult-Onset Dystonia. Ann Neurol, 2001;49:405-408.

Becker G, Berg D, Francis M, Naumann M. Evidence for disturbances of copper metabolism in dystonia. Neurology 2001;57:2290-2294.

Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Muller-Myhsok B, Riedel L, Bauer M, Muller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001; 29: 66-69.

Wunderlich S, Reiners K, Gasser T, Naumann M. Cervical dystonia in monozygotic twins: Case report and review of the literature. Mov Disord 2001; 16: 714-718.

Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, deLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Kramer P, Brin MF, Ozelius LJ, Breakefield XO. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001; 3: 133-143.

Asmus F, Zimprich A, Naumann M, Berg D, Bertram L, Ceballos-Baumann A, Pruszak-Seel R, Kabus C, Dichgans M, Fuchs S, Müller-Myhsok B, Gasser T. Inherited Myoclonus-Dystonia Syndrome: Narrowing the 7q21-q31 Locus in German Families. Ann Neurol 2001; ??: 121-124.

Berg D, Weishaupt A, Francis MJ, Miura N, Yang XL, Goodyer I, Naumann M, Koltzenburg M, Reiners K, Becker G.Changes of Copper Transporting Proteins and Ceruloplasmin in the Lentiform Nuclei in Primary Adult-Onset Dystonia. Ann Neurol 2000;47:827-30.

Kamm C, Naumann M, Mueller J, Mai N, Riedel L, Wissel J, Gasser T. The DYT1 GAG deletion is infrequent in sporadic and familial writer' s cramp. Mov Disord 2000; 15: 1238-1241.

Kamm C, Castelon-Konkiewitz E, Naumann M, Heinen F, Brack M, Nebe A, Ceballos-Baumann A, Gasser T. GAG deletion in the DYT1 gene in early limb-onset idiopathic torsion dystonia in Germany. Mov Disord 1999; 14: 681-683.

Gasser T. Inherited myoclonus-dystonia syndrome. Adv Neurol 1998; 78:325-34: 325-334.

Gasser T, Windgassen K, Bereznai B, Kabus C, Ludolph AC. Phenotypic expression of the DYT1-mutation: a family with writer's cramp of juvenile onset. Ann Neurol 1998; 44: 126-128.

Gasser T. Idiopathic, myoclonic and Dopa-responsive dystonia. Curr Opin Neurol 1997; 10: 357-362.

Gasser T, Bereznai B, Müller B, Pruszak-Seel R, Damrich R, Deuschl G, Oertel WH. Linkage studies in alcohol-responsive myoclonic dystonia. Mov Disord 1996; 12: 363-370.

Gasser T, Bove CM, Ozelius LJ, Hallett M, Charness ME, Hochberg FH, Breakefield XO. Haplotype analysis at the DYT1 locus in Ashkenazi Jewish patients with occupational hand dystonia. Mov Disord 1996; 11: 163-166.


Reviews

Kamm C. Idiopathic torsion dystonia. Orphanet Encyclopedia, May 2004. http://www.orpha.net/data/patho/GB/uk-IdiopathicTorsionDystonia.pdf

Asmus F, Gasser T. Genetics and molecular pathogenesis of myoclonus-dystonia. Nervenheilkunde 2004a; 23: 99-103.

Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol 2004b; 94: 113-9.

Articles
Schmitz-Hubsch T, Tezenas du Montcel S, Baliko L, Boesch S, Bonato S, Fancellu R, et al. Reliability and validity of the International Cooperative Ataxia Rating Scale: A study in 156 spinocerebellar ataxia patients. Mov Disord 2006.

Konieczny M, Bauer P, Tomiuk J, Weisser G, Haan J, Berger K, et al. CAG repeats in Restless Legs syndrome. Am J Med Genet B Neuropsychiatr Genet 2006;141(2):173-6.

Schols L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2005;112(6):789-96.

Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005.

Rub U, Brunt ER, Gierga K, Seidel K, Schultz C, Schols L, et al. Spinocerebellar ataxia type 7 (SCA7): first report of a systematic neuropathological study of the brain of a patient with a very short expanded CAG-repeat. Brain Pathol 2005;15(4):287-95.

Rub U, Del Turco D, Burk K, Diaz GO, Auburger G, Mittelbronn M, et al. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol 2005;31(2):127-40.

Rub U, Gierga K, Brunt ER, de Vos RA, Bauer M, Schols L, et al. Spinocerebellar ataxias types 2 and 3: degeneration of the precerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural Transm 2005.

Klebe S, Durr A, Rentschler A, Hahn-Barma V, Abele M, Bouslam N, et al. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol 2005;58(5):720-9.

Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005;128(Pt 8):1855-60.

Gierga K, Burk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C, et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol (Berl) 2005;109(6):617-31.

Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, et al. Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. Mov Disord 2005;20(9):1191-1194.

Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004;109(1-2):110-4.

Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3(5):291-304.

Schols L, Meyer C, Schmid G, Wilhelms I, Przuntek H. Therapeutic strategies in Friedreich's ataxia. J Neural Transm Suppl 2004(68):135-45.

Schols L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2004.

Saft C, Andrich JE, Neuen-Jacob E, Schmid G, Schols L, Amoiridis G. Supracubital perineurioma misdiagnosed as carpal tunnel syndrome: case report. BMC Neurol 2004;4(1):19.

Rub U, Burk K, Schols L, Brunt ER, de Vos RA, Diaz GO, et al. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. Neurology 2004;63(7):1258-63.

Postert T, Eyding J, Berg D, Przuntek H, Becker G, Finger M, et al. Transcranial sonography in spinocerebellar ataxia type 3. J Neural Transm Suppl 2004(68):123-33.

Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004;36(3):225-7.

Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 2004;24(4):321-9.

Grundmann K, Laubis-Herrmann U, Dressler D, Vollmer-Haase J, Bauer P, Stuhrmann M, et al. Lack of mutations in the epsilon-sarcoglycan gene in patients with different subtypes of primary dystonias. Mov Disord 2004;19(11):1294-7.

Grundmann K, Laubis-Herrmann U, Dressler D, Vollmer-Haase J, Bauer P, Stuhrmann M, et al. Mutation at the SCA17 locus is not a common cause of primary dystonia. J Neurol 2004;251(10):1232-4.

Schulte T, Miterski B, Bornke C, Przuntek H, Epplen JT, Schols L. Neurophysiological findings in SPG4 patients differ from other types of spastic paraplegia. Neurology 2003;60(9):1529-32.

Schulte T, Bohringer S, Schols L, Muller T, Fischer C, Riess O, et al. Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease. J Neural Transm 2003;110(7):749-55.

Schols L, Bauer I, Zuhlke C, Schulte T, Kolmel C, Burk K, et al. Do CTG expansions at the SCA8 locus cause ataxia? Ann Neurol 2003;54(1):110-5.

Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 2003;54(3):367-75.

Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 2003;12(11):1223-31.

Kruger R, Fischer C, Schulte T, Strauss KM, Muller T, Woitalla D, et al. Mutation analysis of the neurofilament M gene in Parkinson's disease. Neurosci Lett 2003;351(2):125-9.

Holzmann C, Kruger R, Saecker AM, Schmitt I, Schols L, Berger K, et al. Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm 2003;110(1):67-76.

Grundmann K, Laubis-Herrmann U, Bauer I, Dressler D, Vollmer-Haase J, Bauer P, et al. Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. Arch Neurol 2003;60(9):1266-70.

Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients. Neurology 2003;60(10):1674-5.

Wintermeyer P, Riess O, Schols L, Przuntek H, Miterski B, Epplen JT, et al. Mutation analysis and association studies of nuclear factor-kappaB1 in sporadic Parkinson's disease patients. J Neural Transm 2002;109(9):1181-8.

Schwenkreis P, Tegenthoff M, Witscher K, Bornke C, Przuntek H, Malin JP, et al. Motor cortex activation by transcranial magnetic stimulation in ataxia patients depends on the genetic defect. Brain 2002;125(Pt 2):301-9.

Schulte T, Schols L, Muller T, Woitalla D, Berger K, Kruger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 2002;326(1):70-2.

Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002;51(3):302-10.

Sauter S, Miterski B, Klimpe S, Bonsch D, Schols L, Visbeck A, et al. Mutation analysis of the spastin gene (SPG4) in patients in Germany with autosomal dominant hereditary spastic paraplegia. Hum Mutat 2002;20(2):127-32.

Rahner N, Holzmann C, Kruger R, Schols L, Berger K, Riess O. Neurofilament L gene is not a genetic factor of sporadic and familial Parkinson's disease. Brain Res 2002;951(1):82-6.

Bornke C, Schmid G, Szymanski S, Schols L. Vertebral body infarction indicating midthoracic spinal stroke. Spinal Cord 2002;40(5):244-7.

Abele M, Burk K, Schols L, Schwartz S, Besenthal I, Dichgans J, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002;125(Pt 5):961-8.

Schulte T, Mattern R, Berger K, Szymanski S, Klotz P, Kraus PH, et al. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001;58(9):1451-7.

Schols L, Vorgerd M, Schillings M, Skipka G, Zange J. Idebenone in patients with Friedreich ataxia. Neurosci Lett 2001;306(3):169-72.

Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001;56(10):1355-62.

Kruger R, Schols L, Muller T, Kuhn W, Woitalla D, Przuntek H, et al. Evaluation of the gamma-synuclein gene in German Parkinson's disease patients. Neurosci Lett 2001;310(2-3):191-3.

Figueroa KP, Chan P, Schols L, Tanner C, Riess O, Perlman SL, et al. Association of moderate polyglutamine tract expansions in the slow calcium-activated potassium channel type 3 with ataxia. Arch Neurol 2001;58(10):1649-53.

Bit-Avragim N, Perrot A, Schols L, Hardt C, Kreuz FR, Zuhlke C, et al. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med 2001;78(11):626-32.

Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D, et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 2000;11(10):2079-82.

Vorgerd M, Schols L, Hardt C, Ristow M, Epplen JT, Zange J. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 2000;10(6):430-5.

Schulz JB, Dehmer T, Schols L, Mende H, Hardt C, Vorgerd M, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55(11):1719-21.

Schols L, Szymanski S, Peters S, Przuntek H, Epplen JT, Hardt C, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000;107(2):132-7.

Schols L, Peters S, Szymanski S, Kruger R, Lange S, Hardt C, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57(10):1495-500.

Kruger R, Menezes-Saecker AM, Schols L, Kuhn W, Muller T, Woitalla D, et al. Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. Neuroreport 2000;11(11):2439-42.

Kruger R, Hardt C, Tschentscher F, Jackel S, Kuhn W, Muller T, et al. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J Neural Transm 2000;107(5):553-62.

Hebinck J, Hardt C, Schols L, Vorgerd M, Briedigkeit L, Kahn CR, et al. Heterozygous expansion of the GAA tract of the X25/frataxin gene is associated with insulin resistance in humans. Diabetes 2000;49(9):1604-7.

Amoiridis G, Schols L. Is the sural nerve a pure sensory nerve? Muscle Nerve 2000;23(12):1895-6.

Kruger R, Vieira-Sacker AM, Kuhn W, Muller T, Woitalla D, Schols L, et al. Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication. J Neural Transm 1999;106(2):159-63.

Kruger R, Vieira-Saecker AM, Kuhn W, Berg D, Muller T, Kuhnl N, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45(5):611-7.

Klockgether T, Schols L, Abele M, Burk K, Topka H, Andres F, et al. Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). J Neurol Neurosurg Psychiatry 1999;66(2):222-4.

Dichgans M, Schols L, Herzog J, Stevanin G, Weirich-Schwaiger H, Rouleau G, et al. Spinocerebellar ataxia type 6: evidence for a strong founder effect among German families. Neurology 1999;52(4):849-51.

Schols L, Kruger R, Amoiridis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998;64(1):67-73.

Schols L, Haan J, Riess O, Amoiridis G, Przuntek H. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998;51(6):1603-7.

Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 1998;8(4):669-79.

Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18(2):106-8.

Klockgether T, Ludtke R, Kramer B, Abele M, Burk K, Schols L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998;121 ( Pt 4):589-600.

Amoiridis G, Schols L, Przuntek H, Wohrle J. Collision technique in Martin-Gruber anastomosis. Muscle Nerve 1998;21(10):1354-6.

Schols L, Amoiridis G, Langkafel M, Schols S, Przuntek H. Motor evoked potentials in the spinocerebellar ataxias type 1 and type 3. Muscle Nerve 1997;20(2):226-8.

Schols L, Riess O, Amoiridis G, Riess A, Przuntek H, Epplen JT. [Genetic diagnosis, classification and clinical hereditary ataxia disease entities]. Fortschr Neurol Psychiatr 1997;65(2):79-89.

Schols L, Gispert S, Vorgerd M, Menezes Vieira-Saecker AM, Blanke P, Auburger G, et al. Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. Arch Neurol 1997;54(9):1073-80.

Schols L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997;42(6):924-32.

Schols L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997;120 ( Pt 12):2131-40.

Riess O, Epplen JT, Amoiridis G, Przuntek H, Schols L. Transmission distortion of the mutant alleles in spinocerebellar ataxia. Hum Genet 1997;99(2):282-4.

Riess O, Schols L, Bottger H, Nolte D, Vieira-Saecker AM, Schimming C, et al. SCA6 is caused by moderate CAG expansion in the alpha1A-voltage-dependent calcium channel gene. Hum Mol Genet 1997;6(8):1289-93.

Riess O, Laccone FA, Gispert S, Schols L, Zuhlke C, Vieira-Saecker AM, et al. SCA2 trinucleotide expansion in German SCA patients. Neurogenetics 1997;1(1):59-64.

Haupt A, Schols L, Przuntek H, Epplen JT. Polymorphisms in the PMP-22 gene region (17p11.2-12) are crucial for simplified diagnosis of duplications/deletions. Hum Genet 1997;99(5):688-91.

Epplen C, Epplen JT, Frank G, Miterski B, Santos EJ, Schols L. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997;99(6):834-6.

Amoiridis G, Schols L, Ameridis N, Przuntek H. Motor fibers in the sural nerve of humans. Neurology 1997;49(6):1725-8.

Schols L, Amoiridis G, Epplen JT, Langkafel M, Przuntek H, Riess O. Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. J Neurol Neurosurg Psychiatry 1996;61(5):466-70.

Klockgether T, Kramer B, Ludtke R, Schols L, Laccone F. Repeat length and disease progression in spinocerebellar ataxia type 3. Lancet 1996;348(9030):830.

Amoiridis G, Schols L, Meves S, Przuntek H. Fact and fallacy in clinical and electrophysiological studies of anomalous innervation of the intrinsic foot muscles. Muscle Nerve 1996;19(9):1227-9.

Amoiridis G, Meves S, Schols L, Przuntek H. Reversible urinary retention as the main symptom in the first manifestation of a syringomyelia. J Neurol Neurosurg Psychiatry 1996;61(4):407-8.

Amoiridis G, Schols L, Pohlau D, Berger K, Niemczyk W, Przuntek H. [Drug-induced rhabdomyolysis and lesions of peripheral nerves. Sequelae of local ischemia within the scope of circulatory collapse?]. Nervenarzt 1996;67(12):1023-6.


Books
Rieß O, Schöls L (eds) Neurogenetik. Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Stuttgart, Verlag Kohlhammer, 2002

Rieß O, Schöls L (eds) Neurogenetik. Molekulargenetische Diagnostik neurologischer Erkrankungen. Berlin, Springer Verlag, 1998


Bookchapters
Rieß O, Schöls L. Direkte Gendiagnostik und Mutationstypen. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 27-34

Schöls L. Adrenoleukodystrophie. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 215-218

Schöls L, Rieß O. Kupferstoffwechselstörungen. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 218-222

Schöls L. Gilles-de-la-Tourette-Syndrom. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 222-223

Schöls L, Przuntek H, Rieß O. Parkinson-Syndrom. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 232-240

Schöls L, Rieß O. Hereditäre Ataxien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 249-277

Schöls L. Hereditäre Neuropathien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 315-332

Schöls L, Mortier W, Rieß O. Dystrophia myotonica Curschmann-Steinert. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 362-370

Schöls L. Myasthene Syndrome. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer Erkrankungen. Springer Verlag, Berlin 1998: 370-374

Schöls L, Paulson H, Riess O. Spinocerebellar ataxia type 3 /Machado-Joseph disease. In Klockgether T (ed.): Handbook of Ataxia Disorders. Marcel Dekker, New York 2000: 385-423

Schöls L, Schulte T. Molekulare Diagnostik neurologischer Erkrankungen. In: Harrisons Innere Medizin (15. Auflage). McGraw-Hill, ABW Wissenschaftsverlag, Berlin 2002: 2549-2560

Schöls L, Riess O. Einführung und tabellarischer Überblick über genetisch diagnostizierbare neurologische Erkrankungen. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 3-16

Schöls L. Klinische Aspekte der genetischen Diagnostik. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 22-23

Riess O, Schöls L, Horsthemke B. Direkte Gendiagnostik und Mutationstypen. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 27-34

Krüger R, Schöls L, Riess O. Idiopathisches Parkinson-Syndrom. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 326-333

Schöls L. Tremor. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 335-337

Schöls L, Riess O. Spinozerebelläre Ataxien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 367-385

Schöls L, Riess O. Autosomal rezessiv und X-chromosomal vererbte Ataxien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 398-408

Schöls L, Sereda MW, Nave KA. Hereditäre Neuropathien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 448-458

Sereda MW, Schöls L, Nave KA. Molekulargenetische Grundlagen der Charcot-Marie-Tooth Neuropathien (CMT/HMSN). In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 459-469

Schöls L, Mortier W, Riess O. Myotone Dystrophien. In Riess O, Schöls L (Hrsg.): Neurogenetik - Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer Verlag, Stuttgart 2002: 508-514

Globas Ch, Geser F, Wenning G, Schöls L. Multiple system atrophy. In Brice A, Pulst SM (eds): Spinocerebellar degenerations: The ataxias and spastic paraplegias. Elsevier, in press

Dietz V, Schöls L. Syndrom der spastischen Parese und Spastische Spinalparalysen. In: Brandt T, Dichgans J, Diener Ch (Hrsg): Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer Verlag, Stuttgart, 5. Auflage, im Druck

Schöls L, Asmus F. Dystonien und Dyskinesien. In: Brandt T, Dichgans J, Diener Ch (Hrsg): Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer Verlag, Stuttgart, 5. Auflage, im Druck